manilatimes15d
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
Under the terms of the agreement, Samsung Bioepis will be responsible for the development, regulatory registration, manufacture and supply of the product, while Teva will be responsible for ...
Yahoo Finance15d
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
EPYSQLI is a complement inhibitor indicated for the treatment of rare disease patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS ...
Nasdaq15d
Samsung Bioepis and Teva Pharmaceutical Enter Partnership for EPYSQLI® Biosimilar to Enhance Treatment Options for Rare Disease Patients in the U.S.
EPYSQLI's approval by the FDA represents a milestone for Teva, potentially increasing revenue and market share in the fast-growing biosimilars market. Teva's commercial responsibilities for ...